Medytox (086900) reported a consolidated operating profit of KRW 7.4 billion for the first quarter of this year, a 34.6% increase compared to the same period last year, according to a regulatory filing on May 12. Revenue fell 5.1% year-on-year to KRW 60.7 billion, while net profit surged 135.7% to KRW 7.9 billion.
A Medytox official attributed the results to "management strategies focused on strengthening core business competitiveness and improving profitability, centered on our main botulinum toxin products." The company noted sustained growth of Medytoxin and Neurux in overseas markets, while in the domestic market, increased sales of the premium toxin product Coretox positively impacted profitability.
Medytox has been strengthening its aesthetic portfolio, including the launch of 'New Viju,' a submental fat reduction injectable, in March. The company plans to expand market competitiveness based on these products and pursue global expansion strategies for key products.
Source: Read the original report | Published: May 12, 2026